IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
IMMUNIC, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$6.99+0.02 (+0.29%)
Close on Oct 19, 2026
- Market cap
- $297.17M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$1.01 (−12.66%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $297.17M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.33
- Dividend yield
- 0.00%
- Free cash flow yield
- -29.63%
Fundamentals
- Net income
- -$111.57M
- EPS, diluted
- -$4.17
- Free cash flow
- -$88.05M
- Book value per share
- $3.00
- Diluted shares
- 43M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$117.88M
Net income
-$111.57M
EPS, diluted
-$4.17
Free cash flow
-$88.05M
Reported periodTrailing twelve months